Differentiation and definition of vascular-targeted therapies

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 416-420

  Siemann, Dietmar W ^a   Bibby, Michael C ^b   Dark, Graham G ^c   Dicker, Adam P ^d   Eskens, Ferry A L M ^e   Horsman, Michael R ^f   Marmé, Dieter ^g   LoRusso, Patricia M ^h  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g TUMOR BIOLOGY CENTER   (Germany)

^h KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; BEVACIZUMAB; CADHERIN; CILENGITIDE; COMBRETASTATIN; CYTOKINE; ENDOSTATIN; FLAVONOID; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; THALIDOMIDE; THROMBOSPONDIN; TUBULIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; VATALANIB; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; ISCHEMIA; METASTASIS; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NOMENCLATURE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SYMPTOMATOLOGY; TARGET CELL; TAXONOMY;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 12244292196     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-12.
2. Marme D. The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003;129:607-20.
3. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
5. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999;29:733-6.
6. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42 Suppl 1:S81-91.
7. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7.
8. Siemann DW. Vascular targeting agents. Horizons in Cancer Therapeutics 2002;3:4-14.
9. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80 Suppl 1:57-64.
10. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
11. Ellis LM, Liu W, Ahmad SA, et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 2001;28:94-104.
12. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90.
13. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9.
14. Starnes CO. Coley's toxins in perspective. Nature 1992;357:11-2.
15. Kim DK, Kinne DW, Fortner JG. Occlusion of the hepatic artery in man. Surg Gynecol Obstet 1973;136:966-8.
16. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
17. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
18. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
20. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5 Suppl 1:3-10.
21. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
22. Bates DO, Heald RI, Curry FE, Williams B. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol 2001;533:263-72.
23. Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-61.
24. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
25. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.
26. Sorbera LA, Leeson PA, Bayés M. Bevacizumab Oncolytic. Drugs of the Future 2002;27:625-32.
27. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
28. Drevs J, Esser N, Konerding MA, et al. Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis, vessel density and microvascular architecture in murine renal cell carcinoma. Proc Am Assoc Cancer Res 2002;43:1082.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
30. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443-50.
31. Seed L, Slaughter DP, Limarzi LR. Effect of colchicine on human carcinoma. Surgery 1940;7:696-709.
32. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1497-502.
33. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001;2:82-7.
34. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.